A 3-year-old girl is diagnosed with Stage IV neuroblastoma with MYCN amplification and unfavorable histology. After induction chemotherapy and stem cell transplantation, she is in remission. Which agent is the preferred choice for maintenance therapy to reduce relapse risk?

Explanation

## Maintenance Therapy in High-Risk Neuroblastoma **Key Point:** Isotretinoin (13-cis-retinoic acid) is the gold-standard maintenance agent for high-risk neuroblastoma after intensive induction and stem cell transplantation. ### High-Risk Neuroblastoma Treatment Paradigm ```mermaid flowchart TD A[High-Risk Neuroblastoma<br/>MYCN amplified or Stage IV]:::outcome --> B[Induction Chemotherapy<br/>Cyclophosphamide, Doxorubicin,<br/>Cisplatin, Etoposide]:::action B --> C[Surgical Resection]:::action C --> D[Myeloablative Chemotherapy<br/>+ Autologous Stem Cell<br/>Transplantation]:::action D --> E{Remission Achieved?}:::decision E -->|Yes| F[Isotretinoin Maintenance<br/>6 cycles x 14 days on/off]:::action E -->|No| G[Salvage Therapy/<br/>Clinical Trial]:::urgent F --> H[Long-term Surveillance]:::outcome ``` ### Isotretinoin: Mechanism and Evidence **Mechanism of Action:** 1. Vitamin A derivative (retinoid) that promotes differentiation of neuroblastoma cells. 2. Induces apoptosis and inhibits proliferation of minimal residual disease. 3. Acts as a biologic agent rather than cytotoxic chemotherapy. **Clinical Evidence:** - **COG Study A3973** demonstrated that isotretinoin maintenance significantly improved event-free survival (EFS) and overall survival (OS) in high-risk neuroblastoma patients who achieved remission after induction and transplantation. - **Standard regimen:** Isotretinoin 160 mg/m²/day orally for 14 days, repeated every 28 days for 6 cycles. - **Survival benefit:** ~20% improvement in 5-year EFS compared to observation alone. **High-Yield:** Isotretinoin is the ONLY maintenance agent with proven survival benefit in high-risk neuroblastoma and is now standard of care in all major protocols (COG, SIOP, GPOH). ### Why Isotretinoin Is Superior | Feature | Isotretinoin | Topotecan | Ifosfamide | Vincristine | |---------|--------------|-----------|-----------|-------------| | **Mechanism** | Differentiation agent | Topoisomerase I inhibitor | Alkylating agent | Microtubule inhibitor | | **Proven maintenance benefit** | ✓ Yes (COG A3973) | ✗ No | ✗ No | ✗ No | | **Tolerated in remission** | ✓ Good | ✗ Myelosuppression | ✗ Myelosuppression | ✗ Neuropathy | | **Standard of care** | ✓ Yes | ✗ Induction only | ✗ Induction only | ✗ Induction only | **Clinical Pearl:** Isotretinoin is given orally and is well-tolerated during maintenance phase. Common side effects include dry skin, mucositis, and elevated liver enzymes—all manageable and reversible. The drug is teratogenic, so careful counseling is needed if the patient reaches reproductive age. **Warning:** Do not confuse isotretinoin with other retinoids (tretinoin, alitretinoin). Isotretinoin (13-cis-retinoic acid) is the specific agent used in neuroblastoma; tretinoin is used in acute promyelocytic leukemia.